Emma Cheetham

Emma is a fully qualified European Patent Attorney with over 20 years’ experience in the pharmaceutical industry.

Emma has a deep knowledge of patenting compounds in the natural product area gained from building established portfolios for the first approved cannabinoid medicines.  During her time at Jazz Pharmaceuticals, formerly GW Pharmaceuticals, she was instrumental in generating an impressive patent portfolio for multiple sclerosis drug, Sativex and more recently the epilepsy medicine Epidiolex, with over 20 patents listed in the Orange Book in the US and strong protection worldwide. 

In addition to direction and strategic management of patents, Emma has extensive experience in leading IP activities for licensing transactions and undertaking due-diligence activities on third party IP, providing training on IP awareness, advising on regulatory data protection for products, overseeing other IP assets such as trade marks, brand protection and trade secrets, and providing support during litigation and determining strategy to help produce strong barriers to entry for products.

Prior to qualifying as a patent attorney, Emma completed her PhD and BSc in Biochemistry.